Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes

Tirzepatide resulted in greater mean reductions in HbA1c and weight compared to semaglutide after 12 months.

• In patients who had not previously used GLP-1 receptor agonists, those on tirzepatide experienced a mean HbA1c reduction of -1.3%, compared to -0.9% for those on semaglutide.
• Patients with prior GLP-1 receptor agonist use on tirzepatide had a mean HbA1c reduction of -0.9%, while those on semaglutide saw a reduction of -0.6%.
• Weight loss after 12 months was greater in the tirzepatide group, with a mean reduction of -10.2 kg in naïve patients versus -6.1 kg in semaglutide patients.
• Non-naïve patients on tirzepatide lost an average of -7.9 kg, compared to -3.7 kg for those on semaglutide.
• Both findings were statistically significant (p < 0.001).

AI simplified